Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.86 USD | -3.50% | +2.11% | +210.40% |
05:21pm | Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study | MT |
05-21 | Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+210.40% | 51.54M | |
+43.30% | 750B | |
+34.11% | 606B | |
-6.18% | 356B | |
+18.90% | 326B | |
+6.61% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+2.35% | 167B |
- Stock Market
- Equities
- LEXX Stock
- News Lexaria Bioscience Corp.
- Transcript : Lexaria Bioscience Corp. Presents at Benzinga Global SmallCAP Conference, Dec-08-2021 09